Abstract:Chronic kidney disease (CKD) is an important and common noncommunicable condition globally. In national and international guidelines, CKD is defined and staged according to measures of kidney function that allow for a degree of risk stratification using commonly available markers. It is often asymptomatic in its early stages, and early detection is important to reduce future risk. The risk of cardiovascular outcomes is greater than the risk of progression to end-stage kidney disease for most people with CKD. C… Show more
“…Haemoglobin A 1c was measured using high-performance liquid chromatography (HPLC), and the outcome was expressed in National Glycohemoglobin Standardisation Program/Diabetes Control and Complication Trial units [32]. Serum creatinine was determined with Jaffe's method and estimated glomelural filtration rate (eGFR) per 1.73 m 2 and was calculated according to the CKD-EPI formula [33]; these results were classified into five stages of the disease (G1-G5) [34]. The UACR was estimated using immunoturbidimetric methods and was drawn from the patients' medical history (we analysed three morning urine samples collected over six months).…”
Introduction: Multifactorial pathogenesis of diabetic kidney disease (DKD) consists of a combination of metabolic, environmental, and genetic factors. A genome-wide association study has shown that ELMO1 is a candidate gene for DKD occurrence and progression. The aim of this study was to assess the association of a single nucleotide polymorphism (rs741301) of the ELMO1 gene with DKD in Polish patients with type 2 diabetes (T2DM). Material and methods: This was a case/control study of 272 T2DM patients with or without DKD. Patients were divided into groups depending on DKD definition according to the American Diabetes Association (ADA) and the National Kidney Foundation (NKF). The association of the rs741301 polymorphism with DKD was assessed in the whole study group as well as in the subgroups stratified according to the presence of DKD. Results: There was no association between rs741301 polymorphisms and the presence of DKD in relation to the ADA definition (p = 0.6) or the NKF definition (p = 0.5) of DKD and with estimated glomelural filtration rate (eGFR) value reflecting the stage of the chronic kidney disease (p = 0.8). Conclusions: Even though the results of this study are negative, there is still a great need for larger studies assessing the genetic susceptibility to DKD to identify patients who are particularly prone to this complication.
“…Haemoglobin A 1c was measured using high-performance liquid chromatography (HPLC), and the outcome was expressed in National Glycohemoglobin Standardisation Program/Diabetes Control and Complication Trial units [32]. Serum creatinine was determined with Jaffe's method and estimated glomelural filtration rate (eGFR) per 1.73 m 2 and was calculated according to the CKD-EPI formula [33]; these results were classified into five stages of the disease (G1-G5) [34]. The UACR was estimated using immunoturbidimetric methods and was drawn from the patients' medical history (we analysed three morning urine samples collected over six months).…”
Introduction: Multifactorial pathogenesis of diabetic kidney disease (DKD) consists of a combination of metabolic, environmental, and genetic factors. A genome-wide association study has shown that ELMO1 is a candidate gene for DKD occurrence and progression. The aim of this study was to assess the association of a single nucleotide polymorphism (rs741301) of the ELMO1 gene with DKD in Polish patients with type 2 diabetes (T2DM). Material and methods: This was a case/control study of 272 T2DM patients with or without DKD. Patients were divided into groups depending on DKD definition according to the American Diabetes Association (ADA) and the National Kidney Foundation (NKF). The association of the rs741301 polymorphism with DKD was assessed in the whole study group as well as in the subgroups stratified according to the presence of DKD. Results: There was no association between rs741301 polymorphisms and the presence of DKD in relation to the ADA definition (p = 0.6) or the NKF definition (p = 0.5) of DKD and with estimated glomelural filtration rate (eGFR) value reflecting the stage of the chronic kidney disease (p = 0.8). Conclusions: Even though the results of this study are negative, there is still a great need for larger studies assessing the genetic susceptibility to DKD to identify patients who are particularly prone to this complication.
“…The problem was ranked 16 th among the leading causes of death in 2016, and is expected to rise to 5 th ranked by 2040 [2]. Chronic kidney disease is defined as an abnormality of kidney function or structure for � 3 months [3] and is a significant burden for individuals, health care systems and societies; it is associated with increased hospitalization, productivity loss, morbidity and early mortality. Diabetic kidney disease is the leading cause of CKD [4]; other common causes include hypertension, glomerulonephritis and autosomal dominant polycystic kidney disease [5].…”
Section: Introductionmentioning
confidence: 99%
“…Chronic kidney disease is classified based on abnormal urinalysis and/or renal tract structure and estimated glomerular filtration rate (eGFR), with the most advanced stage, CKD stage 5, comprising individuals with an eGFR <15 ml/min/1.73m 2 including patients with endstage renal disease (ESRD) [1]. Chronic kidney disease is managed through treatment of its risk factors, such as hypertension and diabetes mellitus [3]. A small proportion of patients with CKD progress to ESRD requiring renal replacement therapy (RRT) with dialysis and/or kidney transplantation (KTx) [6].…”
Chronic kidney disease (CKD) affects over 10% of the global population and poses significant challenges for societies and health care systems worldwide. To illustrate these challenges and inform cost-effectiveness analyses, we undertook a comprehensive systematic scoping review that explored costs, health-related quality of life (HRQoL) and life expectancy (LE) amongst individuals with CKD. Costs were examined from a health system and societal perspective, and HRQoL was assessed from a societal and patient perspective. Papers published in English from 2015 onward found through a systematic search strategy formed the basis of the review. All costs were adjusted for inflation and expressed in US$ after correcting for purchasing power parity. From the health system perspective, progression from CKD stages 1-2 to CKD stages 3a-3b was associated with a 1.1-1.7 fold increase in per patient mean annual health care cost. The progression from CKD stage 3 to CKD stages 4-5 was associated with a 1.3-4.2 fold increase in costs, with the highest costs associated with end-stage renal disease at $20,110 to $100,593 per patient. Mean EuroQol-5D index scores ranged from 0.80 to 0.86 for CKD stages 1-3, and decreased to 0.73-0.79 for CKD stages 4-5. For treatment with renal replacement therapy, transplant recipients incurred lower costs and demonstrated higher HRQoL scores with longer LE compared to dialysis patients. The study has provided a comprehensive updated overview of the burden associated with different CKD stages and renal replacement therapy modalities across developed countries. These data will be useful for the assessment of new renal services/ therapies in terms of cost-effectiveness.
“…Az albuminuria megjelenése jelentősen fokozza a veseelégtelenség és a cardiovascularis betegség, valamint a halálozás kockázatát. 19 Betegünk esetében a 2-es típusú diabetes diagnózisát követően elvégzett vizsgálatok során az eGFR 60 ml/min./1,73 m 2 -nak bizonyult, albuminuria és retinopathia diabetica nem volt kimutatható. Ez a körülmény azt valószínűsíti, hogy a vesefunkció későbbi beszűkülése vélhetően nem lehetett önmagában nephropathia diabetica következménye, hanem abban valószínűsíthetően a nephropathia számos egyéb, a beteg esetében kétségtelenül fennálló rizikótényezője (férfi nem, 70 év feletti életkor, hypertoniabetegség, atherogen dyslipidaemia) is fontos szerepet játszhatott.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.